Morbidity of Metastasectomy for Renal Cell Carcinoma: Emerging

Evidence and Unmet Needs by Minervini, Andrea et al.
E U RO P E AN URO LOGY 7 2 ( 2 0 1 7 ) 1 7 5 – 1 7 6
ava i lable at www.sciencedirect .com
journal homepage: www.europeanurology.comPlatinum Priority – Editorial
Referring to the article published on pp. 171–174 of this issue
Morbidity of Metastasectomy for Renal Cell Carcinoma:
Emerging Evidence and Unmet NeedsAndrea Minervini *, Riccardo Campi, Alberto Lapini, Marco Carini
Department of Urology, University of Florence, Careggi Hospital, Florence, ItalyMetastatic renal cell carcinoma (mRCC) represents a
complex clinical scenario owing to the heterogeneity of
baseline patient and disease characteristics [1].
The dynamic changing paradigm induced by the
introduction of targeted therapies has revolutionized
the treatment philosophy, setting new challenges regarding
the benefit and timing of cytoreductive nephrectomy and
surgical metastasectomy (SM) in the context of multimodal
approaches [2–4]. Current European Association of Urology
(EAU) and European Society of Medical Oncology (ESMO)
guidelines consistently state that no general recommenda-
tions can bemade as towhether a patient should be referred
for SM [5,6]. Nevertheless, the removal of all metastatic
lesions, when technically feasible and clinically appropriate,
provides the only potentially curative treatment for mRCC
patients [3]. Indeed, a recent systemic review and meta-
analysis showed that despite the low quality of evidence
available, median overall survival ranged between 36.5 and
142 mo after complete SM, compared to 8.4–27 mo after
incomplete SM. Incomplete SM cases had greater adjusted
overall mortality, with a hazard ratio of 2.37 (95%
confidence interval 2.03–2.87; p < 0.001) [1]. The results
of a previous systematic review also pointed towards a
benefit of complete SM in terms of overall and cancer-
specific survival, despite the substantial risk of selection
bias and confounding in the studies included [3].
With all of this acknowledged, a relevant question arises.
What is the price to pay for SM inmRCC patients? Assessing
themorbidity of SM plays a key role in decision-making and
in defining the best balance between benefits and harms of
surgery in this complex patient group from urological,
oncological, and public health perspectives. Unfortunately,DOI of original article: http://dx.doi.org/10.1016/j.eururo.2017.03.005.
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literature to date, and represents a critical unmet need.
In this issue of European Urology, Meyer et al [7] describe
in-hospital complication rates after SM in a contemporary
cohort of patients with mRCC. Using the National Inpatient
Sample (NIS) database, they identified 45 279 patients
diagnosed with mRCC between 2000 and 2011. The SM rate
was 2.4%. SM was predominantly performed for lung, bone,
and liver lesions. Overall and major (Clavien III–IV)
complications occurred in 45.7% and 25.1% of patients,
respectively. The in-hospital mortality rate was 2.4%.
On univariate analysis, age and hepatic metastases
(compared to any other site) were independent predictors
of overall complications, while a high comorbidity burden
was an independent predictor of major complications. The
authors also found a significantly lower likelihood of overall
complications among pulmonary resections (compared to
any other site) and of major complications among patients
with private insurance.
The authors should be commended for their valuable
efforts in addressing a complex research need in the rapidly
changing scenario of mRCC. As the NIS represents the
largest publicly available all-payer inpatient health care
database in the USA, a major strength of the study is the
possibility to provide reliable estimates of national rates of
in-hospital complications after SM for RCC. Thus, the study
represents a pioneering first step towards a more compre-
hensive evidence-based definition of perioperative mor-
bidity of SM (and its predictors), opening new perspectives
and research opportunities.
However, caution is needed in clinical interpretation of
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mRCC might not have been observed for a sufficient time
period to see the occurrence of the outcome. Since the data
capture only in-hospital events, morbidity occurring after
discharge could have not been assessed. Therefore, the rate
of complications might have been underestimated owing
to their possible occurrence outside the observational
period. Moreover, a second problem with this scenario is
that the rate of overall and major complications might
have been significantly different among patients under-
going SM for different types of metastases only because of
different lengths of hospital stay. Furthermore, the lack of
a clear operative definition of overall complications could
have led to the inclusion of complications potentially not
related to SM.
Beyond these considerations, a major limitation associat-
ed with the statistical design of the study is the lack of a
multivariate analysis to assess potential associations be-
tween patient-, hospital-, and disease-related characteristics
and the occurrence of in-hospital complications after SM,
which could have led to potentially spurious associations as
those obtained with univariate logistic regression analysis.
Finally, the results presented also have inherent limita-
tions related to the data sources, such as lack of knowledge
on timing of cytoreductive nephrectomy; administration
(and timing) of possible targeted therapy; number, site,
size, and anatomic accessibility of metastases; synchronous
or metachronous interventions; number of metastases
resected at the time of surgery; patient performance status
at surgery and prognostic risk group; intention to treat
(radical vs palliative); type of surgery; and completeness of
SM. These limitations, alongside the aforementioned sources
of bias, inherently prevent any definitive conclusion
regarding the predictors of in-hospital morbidity after SM,
and therefore any guidance for patient counseling. Thus, we
feel that the conclusions of the authors regarding potential
associations between the occurrence of complications and
patient- or hospital-related characteristics might be poten-
tially inconsistent given the strength of evidence provided.
However, Meyer and colleagues should be praised for
their pioneering efforts to fill the gap in knowledge in this
field, providing reliable data on the rate of complicationsafter SM for RCC, opening new perspectives, and outlining
the current unmet research needs.
Our view is that current knowledge on the perioperative
morbidity of SM is, as for many other topics in renal cancer
research, just the tip of an iceberg that we are now starting
to realize. Although many unmet needs are likely to remain
unsolved owing to the inherent difficulties in conducting
studies of a high level of evidence in the setting of this
complex disease, the urology community should strive to
improve the quality of future trial design [8,9] with the aim
of providing more granular and clinically meaningful
answers to the current controversies.
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